Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Clinical & Experimental Metastasis
Erschienen in:

17.06.2022 | Research Paper

Long non-coding RNA NRSN2-AS1, transcribed by SOX2, promotes progression of esophageal squamous cell carcinoma by regulating the ubiquitin-degradation of PGK1

verfasst von: Tongxin Xu, Zhaoyang Yan, Juntao Lu, Liying Chen, Xiaoxu Li, Yan Li, Zhiming Dong, Wei Guo

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Aberrant expression of long non-coding RNAs (lncRNAs) plays pivotal roles in tumorigenesis of human malignant cancers, including esophageal squamous cell carcinoma (ESCC). However, the specific role of lncRNA NRSN2-AS1 in ESCC has not been investigated. Our analysis of clinical data revealed that NRSN2-AS1 was upregulated in ESCC tissues and negatively correlated with patient survival. Luciferase reporter assays and chromatin immunoprecipitation assays demonstrated that NRSN2-AS1 is transcribed by SOX2. In vitro functional experiments showed that NRSN2-AS1 can promote ESCC cell proliferation, migration, and invasion. Furthermore, NRSN2-AS1-binding proteins were detected using RNA pull-down assays and mass spectrometry. Mechanistically, NRSN2-AS1 can bind to phosphoglycerate kinase 1 (PGK1) and upregulate its protein levels by inhibiting its ubiquitination. Knockdown of PGK1 in part abolished the NRSN2-AS1 overexpression-induced effects on ESCC cell proliferation, migration, invasion, and epithelial‑mesenchymal transition (EMT). Thus, NRSN2-AS1 may be a diagnostic biomarker or treatment target for ESCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Yang YM, Hong P, Xu WW et al (2020) Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther 5:229CrossRef
2.
Abnet CC, Arnold M, Wei WQ (2018) Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154:360–373CrossRef
3.
Baba Y, Nomoto D, Okadome K et al (2020) Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci 111:3132–3141CrossRef
4.
Yang J, Liu X, Cao S et al (2020) Understanding esophageal cancer: the challenges and opportunities for the next decade. Front Oncol 10:1727CrossRef
5.
Rajagopal T, Talluri S, Akshaya RL et al (2020) HOTAIR LncRNA: a novel oncogenic propellant in human cancer. Clin Chim Acta 503:1–18CrossRef
6.
Li J, Meng H, Bai Y et al (2016) Regulation of lncRNA and its role in cancer metastasis. Oncol Res 23:205–217CrossRef
7.
Sanchez Calle A, Kawamura Y, Yamamoto Y et al (2018) Emerging roles of long non-coding RNA in cancer. Cancer Sci 109:2093–2100CrossRef
8.
Lin YH (2020) Crosstalk of lncRNA and cellular metabolism and their regulatory mechanism in cancer. Int J Mol Sci 21:2947CrossRef
9.
Zhang Y, Chen W, Pan T et al (2019) LBX2-AS1 is activated by ZEB1 and promotes the development of esophageal squamous cell carcinoma by interacting with HNRNPC to enhance the stability of ZEB1 and ZEB2 mRNAs. Biochem Biophys Res Commun 511:566–572CrossRef
10.
Han GH, Lu KJ, Wang P et al (2018) LncRNA SNHG16 predicts poor prognosis in ESCC and promotes cell proliferation and invasion by regulating Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci 22:3795–3803PubMed
11.
Ren P, Zhang H, Chang L et al (2020) LncRNA NR2F1-AS1 promotes proliferation and metastasis of ESCC cells via regulating EMT. Eur Rev Med Pharmacol Sci 24:3686–3693PubMed
12.
Hu W, Chen Z, Chen J et al (2020) LOC441178 overexpression inhibits the proliferation and migration of esophageal carcinoma cells via methylation of miR-182. Onco Targets Ther 13:11253–11263CrossRef
13.
Chen Q, Xie J, Yang Y (2021) Long non-coding RNA NRSN2-AS1 facilitates tumorigenesis and progression of ovarian cancer via miR-744–5p/PRKX axis. Biol Reprod. ioab212.
14.
Wang J, Gu J, You A et al (2020) The transcription factor USF1 promotes glioma cell invasion and migration by activating lncRNA HAS2-AS1. Biosci Rep 40:BSR20200487CrossRef
15.
Wang H, Huo X, Yang XR et al (2017) STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer 16:136CrossRef
16.
Zhang Y, Yu G, Chu H et al (2018) Macrophage-associated PGK1 phosphory-lation promotes aerobic glycolysis and tumorigenesis. Mol Cell 71:201-215.e7CrossRef
17.
Pastushenko I, Blanpain C (2019) EMT transition states during tumor progression and metastasis. Trends Cell Biol 29:212–226CrossRef
18.
Fu Q, Yu Z (2020) Phosphoglycerate kinase 1 (PGK1) in cancer: a promising target for diagnosis and therapy. Life Sci 256:117863CrossRef
19.
Deng HY, Wang YC, Ni PZ et al (2016) Long noncoding RNAs are novel potential prognostic biomarkers for esophageal squamous cell carcinoma: an overview. J Thorac Dis 8:E653–E659CrossRef
20.
Sugihara H, Ishimoto T, Miyake K et al (2015) Noncoding RNA expression aberration is associated with cancer progression and is a potential biomarker in esophageal squamous cell carcinoma. Int J Mol Sci 16:27824–27834CrossRef
21.
Bian Z, Zhang J, Li M et al (2018) LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res 24:4808–4819CrossRef
22.
Novak D, Hüser L, Elton JJ et al (2020) SOX2 in development and cancer biology. Semin Cancer Biol 67:74–82CrossRef
23.
Porter L, McCaughan F (2020) SOX2 and squamous cancers. Semin Cancer Biol 67:154–167CrossRef
24.
Zhu Y, Huang S, Chen S et al (2021) SOX2 promotes chemoresistance, cancer stem cells properties, and epithelial-mesenchymal transition by β-catenin and Beclin1/autophagy signaling in colorectal cancer. Cell Death Dis 12:449CrossRef
25.
Gao H, Teng C, Huang W et al (2015) SOX2 promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating Slug expression through the activation of STAT3/HIF-α Signaling. Int J Mol Sci 16:21643–21657CrossRef
26.
Ferrè F, Colantoni A, Helmer-Citterich M (2016) Revealing protein-lncRNA interaction. Brief Bioinform 17:106–116CrossRef
27.
Rashid F, Shah A, Shan G (2016) Long non-coding RNAs in the cytoplasm. Genomics Proteomics Bioinformatics 14:73–80CrossRef
28.
Wang Y, Lu JH, Wu QN et al (2019) LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer 18:174CrossRef
29.
Guan Z, Wang Y, Wang Y et al (2020) Long non-coding RNA LOC100133669 promotes cell proliferation in oesophageal squamous cell carcinoma. Cell Prolif 53:e12750CrossRef
30.
Jian F, Che X, Zhang J et al (2021) The long-noncoding RNA SOCS2-AS1 suppresses endometrial cancer progression by regulating AURKA degradation. Cell Death Dis 12:351CrossRef
31.
Jiang H, Li T, Qu Y et al (2018) Long non-coding RNA SNHG15 interacts with and stabilizes transcription factor Slug and promotes colon cancer progression. Cancer Lett 425:78–87CrossRef
32.
Hu H, Zhu W, Qin J et al (2017) Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology 65:515–528CrossRef
33.
He Y, Luo Y, Zhang D et al (2019) PGK1-mediated cancer progression and drug resistance. Am J Cancer Res 9:2280–2302PubMedPubMedCentral
34.
Shao F, Yang X, Wang W et al (2019) Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis. Cancer Commun (Lond) 39:54CrossRef
35.
Santamaria PG, Moreno-Bueno G, Portillo F et al (2017) EMT: Present and future in clinical oncology. Mol Oncol 11:718–738CrossRef
36.
Yang H, Geng YH, Wang P et al (2019) Extracellular ATP promotes breast cancer invasion and epithelial-mesenchymal transition via hypoxia-inducible factor 2α signaling. Cancer Sci 110:2456–2470CrossRef
37.
Cheng L, Gou L, Wei T et al (2020) GBP1 promotes erlotinib resistance via PGK1-activated EMT signaling in non-small cell lung cancer. Int J Oncol 57:858–870CrossRef
38.
Zieker D, Königsrainer I, Tritschler I et al (2010) Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. Int J Cancer 126:1513–1520PubMedPubMedCentral
Metadaten
Titel
Long non-coding RNA NRSN2-AS1, transcribed by SOX2, promotes progression of esophageal squamous cell carcinoma by regulating the ubiquitin-degradation of PGK1
verfasst von
Tongxin Xu
Zhaoyang Yan
Juntao Lu
Liying Chen
Xiaoxu Li
Yan Li
Zhiming Dong
Wei Guo
Publikationsdatum
17.06.2022
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 5/2022
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-022-10174-7

Weitere Artikel der Ausgabe 5/2022

Metastasis suppressor NME1 in exosomes or liposomes conveys motility and migration inhibition in breast cancer model systems

  • Research Paper

Review old bone, new tricks

  • Review

Less contrast-enhanced areas within lymph nodes in the delayed phase of contrast-enhanced MRI: a suspicious finding for lymph node metastases

  • Letters to the Editor

Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis

  • Review

Osteoclasts directly influence castration-resistant prostate cancer cells

  • Open Access
  • Research Paper

Gemcitabine induces polarization of mouse peritoneal macrophages towards M1-like and confers antitumor property by inducing ROS production

  • Research Paper

Neu im Fachgebiet Onkologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Duale Checkpointhemmung gegen Melanome verlängert langfristig das Leben

Im Vergleich zu den Überlebenschancen vor der Einführung von Immuncheckpointhemmern (ICI) ist der Fortschritt durch eine ICI-Kombination mit unterschiedlichen Tagets bei fortgeschrittenem Melanom erstaunlich. Das belegen die finalen Ergebnisse der CheckMate-067-Studie und geben Betroffenen "Hoffnung auf Heilung".

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise